CSIMarket


Kalvista Pharmaceuticals Inc   (KALV)
Other Ticker:  
 


 

Kalvista Pharmaceuticals Inc

KALV's Financial Statements and Analysis



Kalvista Pharmaceuticals Inc narrowed second quarter of 2024 net loss per share of $-0.80 compare to net loss per share of $-0.90 recorded in the same quarter a year ago a decrease compare to $-0.74 realized in previous quarter.


second quarter of 2024
Earnings Per Share Revenues
$ -0.8 $  0 Mill
$+0.10     Unch.    



Kalvista Pharmaceuticals Inc 's Revenue fell by 0 % in second quarter of 2024 (Oct 31 2023) year on year, to $0 million and declined by sequentially.


Kalvista Pharmaceuticals Inc is

More on KALV's Income Statement



Kalvista Pharmaceuticals Inc 's in thesecond quarter of 2024 recorded net loss of $-27.650 million, an increase from net loss of $-22.257 million in II. Quarter a year ago.

Sequentially net loss advanced

More on KALV's Growth

Kalvista Pharmaceuticals Inc Inventories
KALV's Cash flow In the second quarter of 2024 company's net cash flow was $8 million, capital expenditures fell by -0.1926.77%, to $0 millions compare to same quarter a year ago

More on KALV's Cash flow Statement


Kalvista Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Kalvista Pharmaceuticals Inc payed $ -2.27 cash per share, on a free-cash flow basis .

Book value fell by -18.22 % sequentially to $3.31 per share, -24.73% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.31 per share from $ 4.05.

Company issued 0.15 million shares or 0.44 % in Oct 31 2023.


More on KALV's Dividends

 Market Capitalization (Millions) 412
 Shares Outstanding (Millions) 35
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -101
 Cash Flow (TTM) (Millions $) 19
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Kalvista Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Kalvista Pharmaceuticals Inc had negative $ -2.27 cash flow per share, on a free-cash flow basis .

Book value fell by -18.22 % sequentially to $3.31 per share, -24.73% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.31 per share from $ 4.05.

Company issued 0.15 million shares or 0.44 % in Oct 31 2023.


More on KALV's Balance Sheets

 Market Capitalization (Millions) 412
 Shares Outstanding (Millions) 35
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -101
 Cash Flow (TTM) (Millions $) 19
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Kalvista Pharmaceuticals Inc Earnings

Kalvista Pharmaceuticals Inc witnesses a substantial surge in business costs during the second quarter of 2024

The Major Pharmaceutical Preparations sector consultants are currently analyzing the second-quarter performance of KalVista Pharmaceuticals Inc. in 2024. The company reported an operating shortfall of $-29.746 million, with no revenue generated during the August to October 31, 2023 reporting season. Despite this, stakeholders remain optimistic about potential revenue sources in the near future.
It is not uncommon for companies to go through challenging periods in their quest for profitable revenue sources. In the second quarter of 2024, KalVista reported shortfalls of $-27.650 million, further highlighting the need for additional revenue streams. Shareholders are keen for the company to secure these sour...

Major Pharmaceutical Preparations Company, Kalvista Pharmaceuticals Inc, Faces Operating Deficit of $-29.093 Million in First Quarter of 2024


As an investor closely following the Major Pharmaceutical Preparations industry, it is not uncommon to focus on the big players and their financial performance. However, it is important not to overlook the potential of smaller businesses that can offer unique opportunities. Today, I would like to shed some light on Kalvista Pharmaceuticals, a company that recently announced an operating deficit of $-29.093 million for the first quarter of 2024.
In the midst of a wave of new developments in the industry, Kalvista Pharmaceuticals has been working to establish a profitable business model that could set it apart. Despite its current expertise in Major Pharmaceutical Preparations, shareholders seem less ...

Kalvista Pharmaceuticals Inc Releases Fourth Quarter 2023 Financial Results Amidst Wave of Companies"

As a journalist analyzing the financial results of Kalvista Pharmaceuticals Inc, it is evident that the company has experienced some challenges in the fourth quarter of 2023. With an operating shortfall of $-31.727 million, it is clear that the company did not meet its financial targets during this period.
To provide some context, it is worth comparing these results to the previous year's fourth quarter, where the company reported an operating shortfall of $-26.811 million. This indicates that the financial performance has worsened during this time frame. Additionally, Kalvista Pharmaceuticals Inc's net deficit has also increased, reaching $-26.305 million compared to $-24.113 million in the same three-...


Date modified: 2023-12-08T14:04:57+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com